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Abstract
Background: Newly approved migraine preventive therapies have allowed for rapid control of migraine activity, offering
potential to minimize the burden of migraine. This report summarizes a roundtable discussion convened to analyze
evidence for early onset of prevention, ascertain its clinical relevance, and provide guidance for healthcare professionals in
crafting goals and treatment expectations for patients with migraine initiating preventive therapy.
Methods: A virtual roundtable meeting of migraine clinicians, researchers, and patient advocates convened in October
2020. Participants reviewed and discussed data summarizing patient and healthcare professional perceptions of migraine
prevention and evidence from the peer-reviewed and gray literature to develop corresponding recommendations.
Summary: Evidence from clinical studies of anti-calcitonin gene-related peptide monoclonal antibodies (erenumab,
fremanezumab, galcanezumab, and eptinezumab) and the chemodenervation agent onabotulinumtoxinA indicate that
patients may experience reduction of migraine activity within 7 days of drug administration and early attainment of disease
control is associated with improvements in clinically important outcomes. The roundtable of experts proposes that early
onset be defined as demonstration of preventive benefits within 1 week of treatment initiation. We recommend focusing
discussion with patients around “disease control” and potential benefits of early onset of prevention, so patients can set
realistic preventive therapy goals and expectations.
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Introduction
Migraine is a common and disabling neurologic disorder
that affects more than 1 billion individuals worldwide.1 It is
the most disabling disease in people under the age of 50
years2 and was second only to low back pain as the leading
cause of disability globally in 2016.1 Migraine affects multiple areas of functioning (e.g., family and other relationships, career trajectories, educational achievement,
financial security),3 may limit participation in healthy lifestyle choices (e.g., moderate or vigorous physical activity),4,5 and imposes a significant economic burden on
individuals and on society as a whole.6–9
The negative impacts of migraine often persist despite
treatment.10 Poorly controlled migraine not only extends
the burdens described above, it is also associated with acute
medication overuse (MO)11,12 and medication overuse
headache (MOH)13–16; it may result in the transformation
or chronification of migraine,17–22 the latter of which likely
arises from neuroinflammation and central sensitization
resulting from repeated and prolonged exposure to
migraine activity in genetically susceptible individuals.23,24
While some studies suggest that poorly controlled migraine
may worsen or chronify, other studies suggest that the prevalence of daily headache may stabilize, with 69% of participants with migraine aged 19–20 manifesting the same
predominant headache subtype over a 30-year period.25
Furthermore, in a longitudinal population-based study of
9,944 participants, remission from chronic headache was
observed in 58.2% and was associated with female sex, and
no medication overuse compared to participants with persistent chronic headache.26
The impact of migraine increases with increasing
monthly headache day frequency.3,27–30 It has long been
recognized that patients diagnosed with chronic migraine
(CM) carry much higher levels of disability than those
diagnosed with episodic migraine (EM); however, recent
investigations have shown that patients with highfrequency episodic migraine, defined as 8–14 or 10–14
headache days per month, have levels of disability similar
to CM, prompting a proposal to lower the threshold for CM
diagnosis.27,28,31,32
The American Headache Society consensus statement
(2021)33 recommends that preventive treatment be offered
to patients who experience 6 or more headache days per
month regardless of the degree of associated disability. It
further advises that preventive treatment (both pharmacologic and nonpharmacologic) be offered to/considered for
patients with less frequent attacks that significantly interfere with daily life (associated disability) as well as for
patients who cannot use, do not use, or use more than the
recommended dosage of acute therapies. The goals of preventive therapy for patients with migraine are not only to
reduce headache frequency and duration, but also to reduce
attack severity; improve response to acute treatment/avoid
escalation of use and reliance on poorly tolerated,
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ineffective, or unwanted acute treatments; reduce associated disability and costs; improve functioning; and to
reduce headache-associated psychological distress, enable
patients to self-manage migraine, and improve quality of
life.33
The introduction of migraine-specific preventives with
demonstrated early onset of preventive disease control has
the potential to vastly improve the lives of patients with
migraine, who in the past may have had to wait 2 to 6
months to recognize the benefits of available preventive
therapies.34–36
The objective of this report is to summarize discussions
and recommendations from a roundtable of experts convened to analyze available evidence related to early onset
of preventive disease control, ascertain its clinical relevance, and provide guidance for healthcare professionals
in crafting goals and treatment expectations for patients
with migraine initiating preventive therapy.

Methods
A virtual roundtable meeting attended by migraine clinicians, researchers, and patient advocates was convened and
hosted by H. Lundbeck A/S and Lundbeck Seattle BioPharmaceuticals, Inc. on October 8, 2020. The objective of the
meeting was to discuss migraine preventive therapies, with
a specific focus on the early onset of migraine prevention.
Participants (the authors of this report) reviewed and discussed data summarizing patient and physician perceptions
of migraine preventive disease control and evidence from
the peer-reviewed, gray (i.e., from government, academic,
business, and industry sources),37 and consumer literature
on the benefits of an early onset in migraine preventive
disease control, with an emphasis on issues relevant to
prevention in clinical practice (Table 1). Identified data
were reviewed in order of scientific merit and integrity,
as well as relevance. Recommendations were then developed by the authors, based on their knowledge of identified
literature as well as clinical expertise. These recommendations are described in this report, highlighted in italics. All
authors contributed to this meeting summary.

Results/discussion
Appropriately defining “early onset of prevention”:
Disease control
The authors recommend that migraine prevention should be
broadly defined as “the control of disease activity, including benefits beyond reductions in attacks/days per month
frequency, such as reductions in acute medication use or in
non-pain symptoms present during and between attacks as
well as improvements in patient functionality, satisfaction,
and quality of life. Early onset denotes demonstration of
preventive benefits within one week of treatment
initiation.”
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Table 1. Relevant questions raised during roundtable discussion
for migraine preventive disease control in clinical practice.
 What impact would the early onset of prevention be
expected to have on the patient’s quality of life?
 Does a preventive therapy that offers a rapid reduction in
migraine severity have clinical benefits?
 How would early prevention impact a patient’s ability to
work/return to work?
 What benefits on overall patient outcomes would you expect
to see with an early onset of prevention?
 How would the early onset of prevention be expected to
impact acute medication use?
 Can an early preventive effect reverse disease chronification?
 How is the effect of early prevention different from the
overall reduction in migraine frequency?
 What clinical outcomes (apart from monthly migraine days)
could be utilized to evaluate the benefits of early prevention?
 How important is an early preventive effect in the goal of
preventing disease chronification?
 How meaningful is it that the migraine preventive agent has an
impact on the current attack?
 Would an impact on medication overuse headache be an
indicator of early prevention?
 How would an early onset of prevention impact personal and
overall healthcare costs?
 How would a patient’s personal relationships be affected by
an early onset of prevention?
 Would an early onset of preventive effect be expected to
have an impact on non-migraine comorbidities?

We believe that the term “prevention” may be potentially misleading, since many patients would naturally, if
unconsciously, infer that the goal of preventive intervention is to eliminate the chance of having a migraine. For this
reason, we recommend that prevention be more broadly
defined as “disease control”; that is, its goal is not necessarily to eliminate all migraine attacks (an unrealistic
expectation for a chronic disease), but rather to reduce
overall migraine frequency, attack duration and severity,
migraine-related disability, and disease-related psychological distress. When disease control is achieved, patients
often experience enhanced response to acute treatment and
improved functioning in key domains and in overall healthrelated quality of life. These goals are consistent with those
enumerated by the American Headache Society in their
2021 consensus statement.33
The onset of preventive benefits with traditional oral
migraine preventive therapies is typically expressed in
months, if not longer. Based on trial design and the resulting clinical data for these agents, current guidelines and the
American Headache Society consensus statement recommend that patients who are prescribed oral preventive
therapies should continue treatment for at least 8 weeks
“after achieving the target or usual effective dose.”33 Further, the guidelines recommend that patients who are
experiencing a partial response at that 8-week timepoint
be advised that the medication(s) may take 6 to 12 months
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to achieve a full preventive effect.33 In contrast, evidence
from studies of the anti-calcitonin gene-related peptide
(CGRP) monoclonal antibodies (mAbs; erenumab, fremanezumab, galcanezumab, and eptinezumab) and the chemodenervation agent onabotulinumtoxinA indicate that
patients receiving these newer injectable agents may experience clinically relevant preventive benefits much
sooner—as early as Day 1 and consistently by Day 7
post-administration.38–60 As such, based on the availability
of clinical evidence, we propose that early onset be defined
as the demonstration of preventive benefits within 1 week
of treatment initiation. In the following discussion, we
describe outcomes supportive of this definition.

Impact on migraine and headache attack/day per
month frequency
We acknowledge and agree that “CGRP-targeted mAb for
migraine prevention significantly reduces both migraine
and headache frequency early in the course of treatment
(as early as Day 1 with eptinezumab, Days 1–2 with fremanezumab and galcanezumab, and Week 1 with erenumab) and provides sustained preventive effects for up to
12 weeks post-administration. OnabotulinumtoxinA
reduces headache frequency as early as Week 1 after the
first dose.”
A common primary study endpoint is change in
migraine days over a predefined period (e.g., 4 weeks, 12
weeks, etc.) that is traditionally based on regulatory guidance and requirements.61 We believe, however, that a
reduction in total headache days, severity, or duration
(including migraine and other headache) could be a more
clinically relevant marker of early onset of preventive disease control for patients than migraine days, because
patients more often focus on “days without a headache.”
CGRP-targeted mAbs for migraine preventive disease
control significantly reduce both migraine and headache
frequency early in the course of treatment—as early as Day
1 with eptinezumab, which also demonstrated efficacy after
2 hours when administered during a migraine attack, Day
1–2 with fremanezumab and galcanezumab, and Week 1
with erenumab—and provide sustained preventive disease
control for up to 12 weeks post-administration.42,44–60,62,63
For example, in the PROMISE studies, eptinezumab 100
mg and 300 mg reduced the likelihood of a migraine attack
in the 24 hours post-infusion 50% versus baseline and significantly more than placebo (EM, 14.8% and 13.9% vs
22.5%; CM, 28.6% and 27.8% vs 42.3%, respectively).42,55
In the HALO studies, nearly 80% of patients with EM and
70% of patients with CM who received fremanezumab
reported no headache of at least moderate severity by the
next day following the first injection, versus 67% and 61%
of the placebo groups, respectively.45,59 Similarly, reductions in migraine headache days were greater with galcanezumab than with placebo each day of the first week
following injection in the EVOLVE studies.48
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OnabotulinumtoxinA has also demonstrated an early
onset of preventive efficacy, significantly reducing headache frequency as early as Week 1 after first dose (–0.9
days/week [onabotulinumtoxinA] vs –0.7 days/week [placebo] compared with the week before treatment; p ¼ 0.046
vs placebo).41

Reduced acute medication use
We agree that “a rapid reduction in migraine and headache
frequency can reduce reliance upon acute medications
(including over-the-counter and prescription) and result
in fewer medication trials in the quest to find one that
works, less medication overuse, less frequent development
of medication overuse headache, and fewer side effects and
drug interactions.”
The side effects of acute medications—wooziness/dizziness, fatigue, chest and throat pressure, chest pain,
impaired concentration, and upset stomach, among others64,65—have likely negatively impacted the quality of life
of thousands of patients over the past 50 years, and can be
especially detrimental in patients with comorbid conditions. The potential for gastrointestinal side effects, including gastric ulceration, may preclude acute non-steroidal
anti-inflammatory drug (NSAID) use for acute migraine
in some patients, particularly those with peptic ulcer, bowel
diseases, or hemorrhagic stroke.64 Caffeine-containing
combinations may permit reduced NSAID doses but can
also lead to gastrointestinal disturbances as well as anxiety
and motor unrest.64 Triptans have been associated with
many central nervous system, gastrointestinal, and skinrelated side effects, as well as chest tightness and pain.64
Among patients with EM, acute opioid or barbiturate use
increases the risk for transformation to CM.66 Opioids may
also increase the risk for comorbidities. In the populationbased American Migraine Prevalence and Prevention
(AMPP) study, depression, anxiety, and cardiovascular disease risk factors were higher among opioid users than
among nonusers, as was headache-related healthcare
resource utilization.67 And, as is always the case with
opioids, the potential for abuse and dependence is an obvious concern. While migraine treatment utilizing acute medications may lead to the side effects described above, it is
important to emphasize that not treating migraine may
result in worsening in disease symptoms and overall functioning.3–5,17–22
Acute medication overuse is common and may contribute to transformation from EM to CM. In the Migraine in
America Symptoms and Treatment (MAST) study, a longitudinal cross-sectional survey of adults with migraine in
the United States, 2107/13,649 participants (15.4%)
reported acute medication use that met the definition for
overuse; that is, they were using a triptan, opioid, barbiturate, isometheptene, ergot alkaloid, or combination analgesic 10 days/month or an NSAID or simple analgesic 15
days/month.15 A similar proportion of patients in the
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Chronic Migraine Epidemiology and Outcomes (CaMEO)
study met the criteria for acute medication overuse (2975/
16,789 [17.7%]).68 Although the factors contributing to
transformation are likely complex, reports indicate that
patients with MOH are up to 19.4 times more likely than
non-overusers to experience migraine transformation.19,22
To this end, data from erenumab, eptinezumab, and fremanezumab clinical studies have demonstrated reductions
in acute medication use that were consistent with rapid
reductions in migraine frequency. In the ARISE study,49
which was conducted in patients with EM, erenumab significantly reduced acute migraine–specific medication
treatment days as early as Month 1 (p < 0.05) with further
reductions at Week 12 (1.2 days vs 0.6 days from baseline in the erenumab and placebo groups, respectively [p ¼
0.002]); Week 12 reductions were of even greater magnitude when only patients with baseline acute migraine–specific medication use were considered (2.1 days vs
1.2 days, respectively [p ¼ 0.002]). In a CM study,
patients who received erenumab experienced greater reductions in acute migraine–specific medication treatment days
than did patients who received placebo, whether or not they
had acute medication overuse at baseline. This effect was
present at Month 1, with differences achieving statistical
significance by Month 3 (without overuse, 0.9 [p < 0.05]
to 2.4 [p < 0.001] vs placebo; with overuse, 2.8 [p <
0.001] to 3.3 [p < 0.001] vs placebo).69
Similarly, eptinezumab reduced acute medication use
(ergots, triptans, and analgesics) more than placebo as early
as Month 1 after treatment and across 6 months of treatment in patients with EM in the PROMISE-1 study, with
greater reductions by Month 6 observed in patients with
higher (10 days/month) baseline use (eptinezumab
100 mg, 4.0 days; eptinezumab 300 mg, 7.4 days; placebo, 4.1 days).70 For those with CM and 10 days of
acute headache medication use during PROMISE-2 at
baseline, reductions at Month 1 were 8.7 (100 mg) and
9.4 (300 mg) days with eptinezumab versus 5.1 days
with placebo, which was sustained out to Month 6 (eptinezumab 100 mg, 8.9 days; eptinezumab 300 mg,
11.1 days; placebo, 7.9 days).71
Additionally, a recent post hoc analysis of patients in
PROMISE-2 who were prospectively diagnosed with MOH
found that eptinezumab reduced total days/month of acute
medication use from 20.6 (100 mg) and 20.7 (300 mg) at
baseline to 10.8 (100 mg) and 12.2 (300 mg) over the first
dosing interval (Weeks 1–12) versus from 19.8 to 14.8 with
placebo.72 These reductions were sustained or further
improved with eptinezumab over the second dosing interval. In fact, 50.5% (100 mg) and 49.5% (300 mg) of
eptinezumab-treated patients, versus 27.1% of those receiving placebo, consistently used acute headache medication
at frequencies that were below the diagnostic thresholds for
MOH for all 6 months of treatment.73
Further, when preventive treatment with eptinezumab
was initiated during a migraine attack in patients with
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migraine (in the RELIEF study), the likelihood of acute
medication use for that ongoing attack was reduced within
the first 24 hours after the start of infusion.63
Among patients who overused acute medications at
baseline in the fremanezumab HALO studies (13% of
patients with EM and 54% of patients with CM), significant
proportions reverted to no acute medication overuse at
Month 6 (EM, 61% to 85%; CM, 59% to 65%); this benefit
was maintained through Month 12 (EM 77% to 86%; CM
66% to 68%).74,75 In both HALO studies, reductions in
migraine frequency were evident by Week 4,51,74 as was
reversion from medication overuse to no medication overuse in the CM study.76

Increased functionality/decreased disability
and improved quality of life
The authors agree that “available data indicate that the
CGRP inhibitors and onabotulinumtoxinA increase function, reduce disability, and improve quality of life.”
For patients with migraine, we believe that waiting 4 to
12 weeks for medications to work, let alone longer, can
have serious negative implications. For many patients, the
inability to work for extended periods can adversely impact
job, school, and financial opportunities and success and
place additional strain on relationships, all of which can
lead to loss of self-efficacy and hope. Thus, medications
that quickly address the effects of migraine on the ability to
function have the potential to significantly improve the
lives of these patients. Patients may be able to confidently
return to work or school sooner and be more productive
while there. They may be better able to cope with attacks,
care for their children, make healthy lifestyle choices (e.g.,
increase level of physical activity), and plan and consider
opportunities at work or in social settings. It seems reasonable to expect that increases in days free from headaches
could translate into improvements in one or more of these
parameters. In the non-interventional National Health and
Wellness Survey,77 each incremental increase in headachefree days was associated with a 5% reduction in work days
missed and days of household activities missed. Further, if
not managed appropriately, i.e., quickly, migraine may
have long-term clinical and pathophysiological implications for patients, such as worsening of headache/migraine
day frequency, increased acute medication use, and structural brain changes.78–84
Tools to directly assess impact of migraine and treatment on functionality/disability and quality of life are
sometimes included in clinical trials of preventive migraine
interventions85; many are also useful in clinical practice.86
A variety of both general health and migraine-specific
patient-reported outcome measures (PROMs) have been
utilized for these purposes, 86,87 such as the 36-item
Short-Form Health Survey (SF-36) and MigraineTreatment Optimization Questionnaire. These PROMs
vary in parameters covered, response categories, and recall
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time frames, making selection and interpretation challenging based on context.87 We believe that standardized use
of PROMs in future clinical trials will be invaluable in
evaluating the benefits of an early onset of prevention in
patients with migraine.
Available data indicate that the CGRP inhibitors
increase function, reduce disability, and improve quality
of life (reviewed in Gottschalk et al.88). These achievements would be expected to provide patients with even
more benefits—those that are not easily captured with
available measures. For example, increased functionality
would be expected to provide patients with more time to
spend on healthy lifestyle activities (vs having to rest),
which could further improve their disease control. They
could also potentially aid relationships by giving patients
greater ability to make and fulfill familial and social commitments and by reducing their reliance upon others for
support. Additional studies are needed to examine these
potential effects as well as to determine how quickly these
benefits manifest and whether or not they extend to the
periods between attacks.
The PREEMPT trials—randomized, double-blind,
placebo-controlled studies of onabotulinumtoxinA for the
treatment of CM—indicated functional improvement as
well. In one report, 44.1% of patients who received onabotulinumtoxinA versus 25.4% of patients who received placebo had a 5-point reduction from baseline in the 6-item
Headache Impact Test (HIT-689,90) total score at Week 24
(difference vs placebo, p < 0.001).43 Similarly, all role
function domains of the Migraine-Specific Quality-of-life
Instrument (MSQ91,92) were improved more with onabotulinumtoxinA than with placebo at Week 24 (all p <
0.001).43 For both measures, improvements continued
through Week 56, but differences between the groups that
received onabotulinumtoxinA and placebo in the doubleblind phase (both followed by open-label onabotulinumtoxinA) were no longer statistically significant.43

Reduced anxiety and depression (comorbidities)
The authors agree that “data from fremanezumab and onabotulinumtoxinA studies suggest that these preventive
agents may reduce the symptoms of anxiety and depression
in patients with migraine; however, additional studies are
needed to clarify the impact of the early onset of prevention
on these comorbidities.”
Because anxiety and depression are likely related to
headache pain frequency and intensity,93 early control of
migraine activity would be expected to reduce the severity
of these comorbidities. Comorbidities of migraine increase
as headache day frequency increases.27,93 Few studies
have, however, assessed this potential benefit. In the
HALO-CM trial,76 fremanezumab improved MSQ–Emotional Function domain scores 19.7 to 22.4 points from
baseline to Month 12 (vs 16.7 to 17.3 points in the placebo
groups) and reduced 9-item Patient Health Questionnaire
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(PHQ-9) scores 2.3 to 2.8 points from baseline to Month 12
(vs 1.6 to 2.4 points in the placebo groups). Patients also
self-reported improvements in anxiety in a long-term fremanezumab extension study.94 In a pilot study conducted
in patients with comorbid depression, onabotulinumtoxinA
significantly improved symptoms of depression and anxiety as early as Week 12.95 In the larger open-label COMPEL trial,96 onabotulinumtoxinA treatment was associated
with improvements in symptoms of depression (PHQ-9;
3.7- to 6.3-point reductions) and anxiety (Generalized
Anxiety Disorder [GAD-7]; 5.2- to 8.0-point reductions)
over a 2-year period.96 The speed of onset of these effects
likely varies from patient to patient and is an area requiring
further study.

Increased patient satisfaction and persistence
with therapy
The authors highlight that the “early control of migraine
activity provides patients with more timely validation that
the preventive treatment is working, improving persistence
with therapy.”
Patients who fail to experience benefits of preventive
therapies early and patients who experience side effects
(sometimes before benefits) are likely to be dissatisfied
with the treatment and may fail to give the therapy an
adequate trial. This was demonstrated in the Second International Burden of Migraine Study (IBMS-II), in which
24.0% of patients with EM and 40.8% of patients with
CM discontinued traditional preventive therapy (i.e., antidepressants, anti-epileptics, beta blockers, and calcium
channel blockers), 36.8% to 48.2% (EM and CM, respectively) because they believed the medications were not
working, and 34.2% to 53.2% because of side effects.97
A 2017 retrospective analysis of inpatient, outpatient, and
pharmacy claims for patients with CM indicated that many
patients make the decision to discontinue or switch oral
preventives early—with 50% doing so within 60 days of
initiation.98 There is a real benefit in feeling rapid improvement, as it provides the patients with more timely validation that the preventive is working. This may help explain
why dropouts in the primary study periods of CGRPtargeted therapy trials were low (18%). 42,49–
51,53,55,57,75,98–101

Reduced healthcare utilization/direct costs
The authors agree that “the effects on healthcare resource
utilization and direct costs have yet to be examined in
clinical studies of the newer preventive therapies for
patients with migraine.”
Patients who experience early control of migraine are
likely to use less acute medication than are patients who
must wait for their preventive treatment to start working.
This could also mean fewer emergency department and
urgent care visits, acute intravenous infusions, neuroimaging
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studies, and hospitalizations during this time period and
overall. Because patients often seek medical help not only
for headaches, but also for other migraine-related features,
there is a need for studies to explore relationships between
onset of effect with respect to the full range of disease
variables (e.g., attack frequency, disability, and associated
symptoms and comorbidities) and healthcare resource utilization and costs.
Effects on healthcare resource utilization and direct
costs have yet to be examined in clinical studies of newer
preventive therapies; however, the costs of these preventive
medications, particularly for patients with chronic
migraine, can be high.102 It is interesting to note that in
an analysis of data from the non-interventional US National
Health and Wellness Survey, there was no significant relationship between headache-free days and direct costs
observed.77 This finding underscores the need to examine
the impact of the full range of treatment effects on these
outcomes in future preventive medication trials.

Reduced non-medical costs
The authors similarly agree that “the effects of an early
onset of preventive benefits on non-medical costs have yet
to be examined in clinical studies of patients with
migraine.”
Likewise, effects on non-medical costs have yet to be
examined in clinical studies of newer preventive therapies.
Data from the US National Health and Wellness Survey
indicated that greater freedom from headache (headachefree days) was associated with lower non-medical costs.
Specifically, each headache-free day was associated with
a 4% reduction in non-medical costs related to reduced
work productivity; annualized non-medical costs were
$16,975, $12,564, and $6,919 when stratified by 0–10,
11–20, and 21–26 headache-free days per month,
respectively.77

Reduced risk of transition/chronification
The authors highlight that “the ability to rapidly control
migraine activity with CGRP-targeted agents would be
expected to reduce migraine transformation; however, this
potential benefit has not yet been evaluated in clinical
studies of patients with migraine.”
There are several identified risk factors associated with
increased rates of progression from EM to CM.19,22–24,103
Sociodemographic characteristics (e.g., female sex and low
family socioeconomic status), lifestyle factors (e.g., caffeine consumption, major/stressful life events), comorbidities (e.g., obesity, depression, asthma, noncephalic pain,
head and neck injury), headache day frequency, nonoptimized acute treatment, and overuse/increasing use of
acute migraine medications are all associated with an
increased risk of transformation. Although the effects of
modification of risk factors on the new onset of CM have

Gottschalk et al.
not been established, we believe that it remains good clinical practice to do so. Thus, education and lifestyle modifications remain an important aspect of migraine
management, as do interventions to treat comorbidities,
minimize migraine frequency and duration, and optimize
acute medication use.
Whereas the ability to rapidly control migraine activity
with CGRP-targeted agents would be expected to reduce
migraine transformation, this potential benefit has not yet
been evaluated in clinical studies. It is notable that persistent reversion from CM to EM was reported in post hoc
analysis of data from a long-term erenumab clinical study
in which patients receiving erenumab were more than twice
as likely as patients receiving placebo to revert to EM
during the initial 12-week double-blind phase of the study,
and nearly 96.9% of those experiencing early reversion
maintained this benefit throughout the subsequent 52week open-label study period.104

Additional benefits
We anticipate that there may be additional clinical benefits
of an early onset of migraine preventive disease control,
including reductions in the intensity of average headache
pain, interictal allodynia and neck pain and cognitive
impairment, migraine symptom frequency and duration
(during and between attacks), and prodromal symptoms,
as well as prolongation of the duration of interictal periods.
Outcomes assessing these potential benefits should be
included in future migraine prevention studies.

Discussing the benefits of an early onset of prevention
with patients
We strongly recommend that “clinicians take time to
ensure that patients with migraine have a clear understanding of realistic rates of improvements to expect with preventive therapy and when they may expect to see the
benefits from treatment.”
We believe that clinicians should take time to ensure
that migraine patients have a realistic understanding of the
rates and amount of benefits they may experience with
preventive therapy and the estimated timing. We recommend focusing discussion with patients around “disease
control”; that is, not necessarily curing or eliminating all
migraine attacks (an unrealistic expectation for a chronic
disease), rather describing the benefits of an early onset of
migraine prevention as described above. Clinicians should
also help patients establish realistic expectations for treatment efficacy and disease control. For example, with traditional preventives, many patients experience some
benefits early and then continue to improve over the first
3 to 6 months of treatment. Thus, they should be advised
that this might be the case. Education about time to benefit
with respect to other migraine symptoms—particularly the
patient’s most bothersome symptom—or with a comorbidity,
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such as anxiety, is also important. Satisfaction and compliance with therapy may be enhanced when a patient
recognizes that the time to improvement with respect to
these benefits may differ from time to improvement in
headache.

Conclusion
The goals of migraine management have long focused on
the control of attacks and associated functional impairment
using both acute abortive and preventive therapies. Despite
the potential burden that migraine has on the individual
patient, limited guidance has been provided regarding the
importance of the clinical benefits that patients are provided with the earliest onset of preventive disease control.
Based on the available evidence with the anti-CGRP mAbs
(erenumab, fremanezumab, galcanezumab, and eptinezumab) and chemodenervation agents (onabotulinumtoxinA),
we suggest that a broader approach regarding the goal of
early control of migraine activity be undertaken in managing patients with migraine—one that encompasses effects
on clinically important outcomes, such as acute medication
use, patient function, satisfaction, quality of life, and
comorbidity.
Attainment of disease control early in the process can
reduce both the impact on daily life and potential for transformation that arises from repeated migraine attacks. We
anticipate that these benefits will translate into improved
adherence and persistence with therapy as well as reduced
acute medication use, healthcare resource utilization, and
associated costs. Additional studies are needed to fully elucidate the extent of these effects.
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